EMA begins evaluation of use of 2nd dose of Johnson & Johnson vaccine

The European Medicines Agency (EMA) began this Monday to evaluate an application for the use of a second booster dose of Covid-19 vaccine from Janssen (Johnson & Johnson) for people over 18 years.

The European Medicines Agency (EMA) announced this Monday, in a statement, that it had started an evaluation process for the administration of a Janssen vaccine booster dose at least two months after taking the first dose.

EMA’s Human Medicines Committee will conduct an accelerated review of data submitted by the European subsidiary of Johnson & Johnson pharmaceuticals that markets the vaccine, which include results from more than 14,000 adults who received a second dose of vaccine or placebo (a dummy treatment) two months after the initial dose and you should give your opinion within weeks.

Janssen’s vaccine is a vaccine to prevent Covid-19 and is authorized for use in people aged 18 years and over in a single-dose regimen.

This vaccine is made up of another virus (in the adenovirus family) that has been modified to contain the gene to make a protein from SARS-CoV-2, the virus that causes COVID-19, preparing it to defend against the Covid virus. -19.

The decision on the introduction of a second dose of the vaccine, if approved, rests with the health authorities of the Member States.

Covid-19 has caused at least 5,144,573 deaths worldwide, among more than 256.54 million infections by the new coronavirus recorded since the start of the pandemic, according to the latest report by the Agence France-Presse.

In Portugal, since March 2020, 18,321 people have died and 1,122,283 cases of infection have been recorded, according to data from the General Directorate of Health.

The disease is caused by the SARS-CoV-2 coronavirus, detected in late 2019 in Wuhan, a city in central China, and currently with variants identified in several countries.


Leave a Reply